Nika Pharmaceuticals, Inc 10-Q for FY2022 Q3
Nika Pharmaceuticals, Inc (NIKA)
About this 10-Q
Nika Pharmaceuticals, Inc filed this 10-Q on November 10, 2022, covering the quarter ended September 30, 2022 (FY2022 Q3).
Headline figures
Quarter ended September 30, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net income
- $6339
- up 134.9% from net income of $2699 a year earlier
- Diluted EPS
- $0.00
- compared with $0.00 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period
Commission File No.:
(Exact
name of the small business issuer as specified in its charter)
| (State or Other Jurisdiction of | (I.R.S. Employer | |
| Incorporation or Organization) | Identification No.) |
| (Address of principal executive offices) |
| (Registrant’s telephone number, including area code) |
| (Former name, former address and former fiscal year, if changed since last report) |
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter
period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | [ ] | Accelerated filer | [ ] |
| [X] | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Act).
Yes [
]
The number of shares of Common Stock, $0.001 par value of the registrant outstanding at October 31, 2022 was .
TABLE OF CONTENTS
2
PART I
Item 1. Consolidated Financial Statements
| NIKA PHARMACEUTICALS, INC. |
| (FORMERLY CENTENNIAL GROWTH EQUITIES, INC.) |
| CONSOLIDATED BALANCE SHEETS |
| (UNAUDITED) |
| September 30, 2022 | December 31, 2021 | |||||
| ASSETS | ||||||
| Current Assets: | ||||||
| Cash | $ | |
$ | |
||
| Total current assets | ||||||
| Total Assets | $ | |
$ | |
||
| LIABILITIES
AND STOCKHOLDERS’
EQUITY (DEFICIT) |
||||||
| Current Liabilities: | ||||||
| Due to related party | $ | |
$ | |
||
| Total Current Liabilities | ||||||
| Due to related party - long term | ||||||
| Total Liabilities | ||||||
| Commitments and contingencies | ||||||
| Stockholders' Equity (Deficit): | ||||||
| Preferred
Stock; par value ;
shares authorized; and shares issued and outstanding, respectively |
||||||
| Common
Stock; par value ; shares authorized; and shares issued and outstanding, respectively |
||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ( |
) | ( |
) | ||
| Total Stockholders' Equity (Deficit) | ( |
) | ( |
) | ||
| Total Liabilities and Stockholders' Deficit | $ | |
$ | |
The accompanying notes are an integral part of these unaudited consolidated financial statements.
3
| NIKA PHARMACEUTICALS, INC. |
| (FORMERLY CENTENNIAL GROWTH EQUITIES, INC.) |
| CONSOLIDATED STATEMENTS OF OPERATIONS |
| (Unaudited) |
| For the Three Months Ended | For the Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||
| Operating Expenses: | ||||||||||||
| General and administrative | $ | |
$ | |
$ | |
$ | |
||||
| Consulting expense | ||||||||||||
| Development expense | ||||||||||||
| Total operating expenses | ||||||||||||
| Loss from operations | ( |
) | ( |
) | ( |
) | ( |
) | ||||
| Loss before provision for income taxes | ( |
) | ( |
) | ( |
) | ( |
) | ||||
| Provision for income taxes | ||||||||||||
| Net Loss | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) |
| Loss per share, basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) |
| Weighted average common shares outstanding, basic and diluted | ||||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
4
| NIKA PHARMACEUTICALS, INC. |
| (FORMERLY CENTENNIAL GROWTH EQUITIES, INC.) |
| CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) |
| FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021 |
| (Unaudited) |
| Total | |||||||||||||||||||||
| Preferred Stock | Common Stock | Additional Paid | Accumulated | Stockholders’ | |||||||||||||||||
| Shares | Amount | Shares | Amount | in Capital | Deficit | Equity | |||||||||||||||
| Balances as of December 31, 2021 | — | $ | $ | |
$ | |
$ | ( |
) | $ | ( |
) | |||||||||
| Forgiveness of related party loans | — | — | |||||||||||||||||||
| Net loss | — | — | ( |
) | ( |
) | |||||||||||||||
| Balances as of March 31, 2022 | — | ( |
) | ||||||||||||||||||
| Common stock issued for cash | — | ||||||||||||||||||||
| Common stock issued for services | — | ||||||||||||||||||||
| Preferred stock issued for agreement | — | ||||||||||||||||||||
| Net loss | — | — | ( |
) | ( |
) | |||||||||||||||
| Balances as of June 30,
2022 (Restated) |
( |
) | |||||||||||||||||||
| Net loss | — | — | ( |
) | ( |
) | |||||||||||||||
| Balances as of September 30, 2022 | $ | |
$ | |
$ | |
$ | ( |
) | $ | ( |
) | |||||||||
| Total | |||||||||||||||||||||
| Common Stock | Additional Paid | Accumulated | Stockholders’ | ||||||||||||||||||
| Shares | Amount | in Capital | Deficit | Deficit | |||||||||||||||||
| Balances as of December 31, 2020 | — | $ | |
$ | |
$ | ( |
) | $ | ( |
) | ||||||||||
| Net loss | — | — | ( |
) | ( |
) | |||||||||||||||
| Balances as of March 31, 2021 | — | ( |
) | ( |
) | ||||||||||||||||
| Net loss | — | — | ( |
) | ( |
) | |||||||||||||||
| Balances as of June 30, 2021 | — | ( |
) | ( |
) | ||||||||||||||||
| Net loss | — | — | ( |
) | ( |
) | |||||||||||||||
| Balances as of September 30, 2021 | — | $ | |
$ | |
$ | ( |
) | $ | ( |
) | ||||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
5
| NIKA PHARMACEUTICALS, INC. |
| (FORMERLY CENTENNIAL GROWTH EQUITIES, INC.) |
| CONSOLIDATED STATEMENTS OF CASH FLOWS |
| (Unaudited) |
| For the Nine Months Ended | ||||||
| September 30, | ||||||
| 2022 | 2021 | |||||
| Cash flows from operating activities: | ||||||
| Net Loss | $ | ( |
) | $ | ( |
) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
| Preferred stock issued | ||||||
| Common stock issued for services | ||||||
| Changes in operating assets and liabilities: | ||||||
| Accounts payable | ||||||
| Net cash used in operating activities | ( |
) | ( |
) | ||
| Cash flows from investing activities: | ||||||
| Cash flows from financing activities: | ||||||
| Common stock issued for cash | ||||||
| Loans from related party | ||||||
| Net cash provided by financing activities | ||||||
| Net change in cash | ||||||
| Cash, beginning of period | ||||||
| Cash, end of period | $ | |
$ | |
||
| Supplemental disclosure of cash flow information: | ||||||
| Cash paid for taxes | $ | $ | ||||
| Cash paid for interest | $ | $ | ||||
| Supplemental disclosure of non-cash investing and financing activity: | ||||||
| Forgiveness of related party debt | $ | |
$ | |||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
6
| NIKA PHARMACEUTICALS, INC. |
| (FORMERLY CENTENNIAL GROWTH EQUITIES, INC.) |
| NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS |
| SEPTEMBER 30, 2022 |
NOTE 1 – ORGANIZATION AND OPERATIONS
Nika Pharmaceuticals, Inc. (the “Company” “Nika”), was incorporated in the State of Colorado on June 8, 2000.
On 0, the Company created a subsidiary, Venture Growth Equities, Inc., a Colorado corporation, of which shares of common stock was issued to the Company, making it a wholly owned subsidiary of the Company. There has been no activity in the subsidiary.
On
Mr. Ray was appointed as a Director, CEO, CFO, Secretary and Treasurer of the Company and Mrs. A. Terry Ray, the wife of Mr. Ray, was appointed as a Director of the Company.
On
On April 1, 2022, the board of directors accepted the resignations of Mr. Phil E. Ray and Mrs. A. Terry Ray and appointed Dimitar Slavchev Savov to serve as President, CEO, CFO and Clifford Redekop to serve as Secretary of the Corporation.
As of April 11, 2022, due to the acquisitions of Exclusive Rights Agreements (Note 5) and the updated business scope, the Company is no longer designated as a shell company.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The Company’s unaudited
consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America (“U.S.
GAAP”). The accompanying unaudited consolidated financial statements reflect all
adjustments, consisting of only normal recurring items, which, in the opinion of
management, are necessary for a fair statement of the results of operations for
the periods shown and are not necessarily indicative of the results to be
expected for the full year ending December 31, 2022. These unaudited
consolidated financial statements should be read in conjunction with the
financial statements and related notes included in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2021.
7
Use of Estimates
The preparation of financial
statements in conformity with generally accepted accounting principles requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results may differ from those
estimates.
Cash and Cash Equivalents
For purposes of the
statement of cash flows, the Company considers all highly liquid instruments
purchased with an original maturity of three months or less to be cash
equivalents. As of September 30, 2022 and December 31, 2021, the Company had no
cash equivalents.
Principles of Consolidation
The
unaudited consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries, Centennial Growth Equities and Centennial
Ventures, Inc., (spun out on January 6, 2022). There has been no activity in
either subsidiary as of September 30, 2022.
Recent Accounting Pronouncements
The Company
has implemented all new applicable accounting pronouncements that are in effect
and applicable. These pronouncements did not have any material impact on the
financial statements unless otherwise disclosed, and the Company does not
believe that there are any other new accounting pronouncements that have been
issued that might have a material impact on its financial position or results of
operations.
NOTE 3 - GOING CONCERN
As reflected in the unaudited consolidated financial statements,
the Company has an accumulated deficit of $
NOTE 4 – RELATED PARTY TRANSACTIONS
During the nine months ended September 30, 2022 and 2021, Mr.
Ray loaned the Company $
In conjunction with the sale of the majority shares of the
Company and the change in ownership, Mr. Ray forgave the $
During the nine months ended September 30, 2022,
DimitarSlavchev Savov, CEO, advanced the Company $
Exclusive Rights Agreements
On April 7, 2022, the Company signed with “VITAL FE” Joint
Stock Company (“VITAL”) an Exclusive Rights Agreement for a term of 15 years for
the production and distribution of Thymus Nuclear Glycoprotein (“TNG”). VITAL
holds the technology to manufacture TNG and the intellectual property for Phase
III Clinical Trial on TNG, started in 1997 and completed in 1998 in Infectious
Diseases Hospital, Sofia on 20 patients suffering from AIDS in the advanced
stages of the disease. The results of the clinical trial show that TNG has a
significant place in the treatment of HIV.
8
On April 7, 2022, the Company signed with “MICAR 11” LTD.
(“MICAR”) an Exclusive Rights Agreement for a term of 15 years for the
production and distribution of two dietary supplements, namely Carotilen
and Physiolong. Carotilen is a dietary supplement in the form
of soft gelatin capsules that improves and regulates the metabolism of the
epithelial cells and protects them from degenerative alterations. It favorably
affects embryonic development; the regulation of the growth and division of the
cells; stimulates the growth of the bone tissue; favorably affects the function
of the gonads; increases and maintains high level of the immune system.
Physiolong is a dietary food supplement in the form of hard gelatin
capsules, which serves as general stimulant for those in a period of
convalescence, as well as in situations of high mental and physical loads, and
for the recovery in sports.
NOTE 5 - COMMON STOCK
On April 26, 2022, the Company sold shares of common
stock for $
On April 25, 2022, the Company issued shares of
common stock to Noble Investment Corp. pursuant to the terms of a Consulting
Services Agreement for the goal of getting an active trading symbol and placing
the Company’s common stock on OTC Markets. The shares were valued at , for
total non-cash expense of $
On April 26, 2022, the Company issued shares of
common stock pursuant to the terms of an Intermediation Agreement with the goal
of getting national distribution of the Company’s dietary supplements Physiolong
and Carotilenin the North American markets. The shares were valued at , for
total non-cash expense of $
On April 26, 2022, the Company issued shares of
common stock to MariyaRadivoeva pursuant to the terms of a Services Agreement
with the goal of creating a coherent brand that reflects the entry of Nika
Pharmaceuticals. Inc. into the pharmaceutical industry. The shares were valued
at , for total non-cash expense of $
On April 26, 2022, the Company issued shares of
common stock to Kubrat Radivoev pursuant to the terms of a Services Agreement
with the goal of construction and maintenance of the Company’s own production
facility. The shares were valued at , for total non-cash expense of
$
the Company and its Board of Directors approved a 30 for 1 stock dividend to be issued to all shareholders. The dividend became effective on July 20, 2022. As a result, shares of common stock were issued. The stock dividend is considered to be a forward split in form; therefore, all shares throughout these financial statements have been retroactively adjusted to reflect the split.
On August 18, 2022, the Company Amended its Articles of Incorporation to change the par value of the common
stock from $0.001
to $
NOTE 6– PREFERRED STOCK
On April 8, 2022, the Company filed a certificate of
designation establishing the rights and preference of preferred stock with the
Secretary of State of Colorado, which modified the rights of owners of Preferred
Stock.
On August 18, 2022, the Company Amended its Articles of
Incorporation to change the par value of the preferred stock from $0.001 to
$
Refer to Note 4 for preferred stock issued to a related party.
9
NOTE 7 – OTHER EVENTS
On August 31, 2022, the company signed an Exclusive Rights Agreement with Dimitar Slavchey Savov through which Nika is appointed as an exclusive representative for the production and sale of the dietary supplements Hypocholestin, Dry Boza, Anthocylen C, Fructin, Biodetoxin, Sylimaron within the territories of Europe, Asia, Africa, South America, North America and Australia.
On August 1, 2022, the Company signed a Joint Business Agreement with Immunotech Laboratories BG, Ltd. through which the two companies are combining their efforts to realize the registration, production and distribution of medicinal products based on the Inactivated Pepsin Fraction (“IPF”) platform with U.S. Patents Nº 7,479,538, 7,625,565, 8,066,982, 8,067,531, 8,309,072. The duration of the agreement is for a period of 9 years and will renew automatically for another 9 years unless there are reasonable objections to the renewal by one of the parties.
On August 1, 2022, the Company signed a Cooperation Agreement with Nika BioTechnology, Inc. (OTCMKTS: NIKA) a Nevada Corporation. Pursuant to the agreement, all development of the prescription drug TNG, the dietary supplements Physiolong and Carotilen, as well as any future acquired other patents for prescription drugs and dietary supplements, shall be jointly developed by the parties. The costs of production and distribution will be financed by both parties in equal parts. The net profit – after deduction of all expenses and taxes – will be distributed between the parties in equal parts. The agreement is for a period of 15 years.
NOTE 8 - SUBSEQUENT EVENTS
Management has performed an evaluation of subsequent events through the date that the financial statements were issued and has determined that it has the following material subsequent events to disclose in these unaudited consolidated financial statements.
On , the Company acquired a
10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
This quarterly report on Form 10-Q contains “forward-looking statements” that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new products or services; our statements concerning litigation or other matters; statements concerning projections, predictions, expectations, estimates or forecasts for our business, financial and operating results and future economic performance; statements of management’s goals and objectives; trends affecting our financial condition, results of operations or future prospects; our financing plans or growth strategies; and other similar expressions concerning matters that are not historical facts. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes” and “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements.
Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Business Overview
Nika Pharmaceuticals, Inc. was incorporated in the State of Colorado on June 6, 2000. Pursuant to the terms of a stock purchase agreement resulting in a change of control the Company is changing its business to focus on the following.
On April 7, 2022, the Company signed with “VITAL FE” Joint Stock Company (“VITAL”) an Exclusive Rights Agreement for a term of 15 years for the production and distribution of Thymus Nuclear Glycoprotein (“TNG”). VITAL holds the technology to manufacture TNG and the intellectual property for Phase III Clinical Trial on TNG, started in 1997 and completed in 1998 in Infectious Diseases Hospital, Sofia on 20 patients suffering from AIDS in the advanced stages of the disease. The results of the clinical trial show that TNG has a significant place in the treatment of HIV.
On April 7, 2022, signed with “MICAR 11” LTD. (“MICAR”) an Exclusive Rights Agreement for a term of 15 years for the production and distribution of two dietary supplements, namely Carotilen and Physiolong. Carotilen is a dietary supplement in the form of soft gelatin capsules that improves and regulates the metabolism of the epithelial cells and protects them from degenerative alterations. It favorably affects embryonic development; the regulation of the growth and division of the cells; stimulates the growth of the bone tissue; favorably affects the function of the gonads; increases and maintains high level of the immune system. Physiolong is a dietary food supplement in the form of hard gelatin capsules, which serves as general stimulant for those in a period of convalescence, as well as in situations of high mental and physical loads, and for the recovery in sports.
On August 31, 2022, the company signed an Exclusive Rights Agreement with DimitarSlavchev Savov through which Nika is appointed as an exclusive representative for the production and sale of his products within the territories of Europe, Asia, Africa, South America, North America and Australia.
On August 1, 2022, the Company signed a Joint Business Agreement with Immunotech Laboratories BG, Ltd. through which the two companies are combining their efforts to realize the registration, production and distribution of medicinal products based on the Inactivated Pepsin Fraction (“IPF”) platform with U.S. Patents Nº 7,479,538, 7,625,565, 8,066,982, 8,067,531, 8,309,072. The duration of the agreement is for a period of 9 years and will renew automatically for another 9 years unless there are reasonable objections to the renewal by one of the parties.
On August 1, 2022, the Company signed a Cooperation Agreement with Nika BioTechnology, Inc. (OTCMKTS: NIKA) a Nevada Corporation. Pursuant to the agreement, all development of the prescription drug TNG, the dietary supplements Physiolong and Carotilen, as well as any future acquired other patents for prescription drugs and dietary supplements, shall be jointly developed by the parties. The costs of production and distribution will be financed by both parties in equal parts. The net profit – after deduction of all expenses and taxes – will be distributed between the parties in equal parts. The agreement is for a period of 15 years.
11
On October 11, 2022, the Company acquired a 40% stake in Nika Europe, Ltd. through which the company will have a firm foothold on the markets of Europe, Asia, and Africa. Nika Europe is preparing the construction of a pharmaceutical factory that is comprised of different manufacturing facilities for the production of drugs in injection, tablet and other forms. The factory will have enough production capacity to secure the needs of Nika.
Critical Accounting Policies, Judgments and Estimates
Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Results of Operations for the three months ended September 30, 2022 compared to the three months ended September 30, 2021.
As of September 30, 2022, the Company has had no
revenue.
General and Administrative
General and
Administrative (“G&A”)expenses have primarily consisted of costs related to
filing the Form 10-K and Form 10-Qs for the Company, including audit and
accounting expense and filing fees. For the three months ended September 30,
2022, G&A expenses were $6,339 compared to $2,699 during the three months
ended September 30, 2021, an increase of $3,640 or 134,.8%. The increase is due
to the addition of development costs related to the new business.
Net Loss
During the three months ended
September 30, 2022, the Company incurred a net loss of $6,339, compared to a net
loss of $2,699 during the three months ended September 30, 2021.
Results of Operations for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.
As of September 30, 2022, the Company has had no revenue.
General and Administrative
G&A expenses
have primarily consisted of costs related to filing the Form 10-K and Form 10-Qs for the Company, including audit and accounting
expense and filing fees. For the nine months ended September 30, 2022, G&A expenses were $18,665 compared to $11,412 during the
nine months ended September 30, 2021, an increase of $7,253 or 63.5% . The increase is due to the addition of development costs
related to the new business.
Consulting expense
Consulting expense was
$150,000 and $0 for the nine months ended September 30, 2022 and 2021,
respectively. During the current period the Company issued common stock for
services for total non-cash consulting expense of $150,000.
Development expense
During the current period
the Company issued 10,000,000 shares of preferred stock per the terms of two
Exclusive Rights Agreement (Note 4). The preferred shares were valued at
$3,000,000.
Net Loss
During the nine months ended
September 30, 2022, the Company incurred a net loss of $3,168,665, compared to a
net loss of $11,412 during the nine months ended September 30, 2021. The increase
in net loss is due to expenses associated with the issuance of common and
preferred stock as discussed above.
12
Liquidity and Capital Resources
Operating Activities
Net cash used in operating activities was $18,665 for the nine months ended September 30, 2022, compared to $11,412 for the nine months ended September 30, 2021.
Investing Activities
We neither generated nor used cash in investing activities during the nine months ended September 30, 2022 and 2021.
Financing Activities
During the nine months ended September 30, 2022, we received $12,180 in loan proceeds from related parties and $10,000 from the sale of common stock. During the nine months ended September 30, 2021, we received $11,500 in loan proceeds from a former related party.
Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company currently has limited operations and has an accumulated deficit of $3,320,364. If the Company cannot fulfill its business plan, the Company may attempt to find a merger target in the form of an operating entity. The Company cannot be certain that it will be successful in this strategy.
These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Off Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.
Not applicable to smaller reporting companies.
ITEM 4. CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, they concluded that our disclosure controls and procedures were not effective for the quarterly period ended September 30, 2022.
The following aspects of the Company were noted as potential material weaknesses:
| • lack of an audit committee |
| • lack of separation of duties |
In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.
13
Changes in Internal Controls
Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that no change occurred in the Company's internal controls over financial reporting during the quarter ended September 30, 2022, that has materially affected, or is reasonably likely to materially affect, the Company's internal controls over financial reporting.
PART II
ITEM 1. LEGAL PROCEEDINGS.
There are no legal proceedings against the Company and the Company is unaware of any proceedings contemplated against it.
Item 1A. Risk Factors.
In accordance with the requirements of Form 10-Q, the Company, as a smaller reporting company, is not required to make the disclosure under this item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None
Item 3. Defaults Upon Senior Securities.
None
Item 4. Mine Safety Disclosures.
None
Item 5. Other Information.
None
Item 6. Exhibits.
(a) Exhibits.
| Exhibit | ||
| No. | Description | |
| 31.1 | Rule 13a14(a)/15d-14(a) Certification of Chief Executive Officer and Chief Financial Officer | |
| 32.1 | Section 1350 Certification of Chief Executive Officer and Chief Financial Officer | |
| 101.INS* | Inline XBRL Instance Document(1) | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document(1) | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document(1) | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document(1) | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document(1) | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document(1) |
14
Signatures
Pursuant to the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Nika Pharmaceuticals, Inc. | ||
| Date:November 10, 2022 | By: | /s/ DimitarSlavchev Savov |
| DimitarSlavchev Savov, Chief Executive Officer, | ||
| Director | ||
15
EXHIBIT 31.1
Certification of Chief Executive Officer and Chief Financial
Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of
2002
I, DimitarSlavchevSavov, certify that:
| 1. |
I have reviewed this report on Form 10-Q. | |
|
|
| |
| 2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
|
|
| |
| 3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
|
|
| |
| 4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |
| a) |
Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
|
| ||
| b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
|
| ||
| c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
|
| ||
| d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and | |
| 5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions): | |
|
|
| |
| a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
|
| ||
| b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. | |
| Date: November 10, 2022 | By: | /s/ DimitarSlavchev Savov |
| DimitarSlavchev Savov | ||
| Chief Executive Officer, Director |
16
EXHIBIT 32.1
CERTIFICATION
Pursuant to 18 U.S.C. 1350
(Section 906 of the Sarbanes-Oxley
Act of 2002)
In connection with the Quarterly Report on Form 10-Q of Nika Pharmaceuticals, Inc. (the “Company”) for the quarterended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), DimitarSlavchevSavov, as Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
| (1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
| |
| (2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: November 10, 2022 | By: | /s/ DimitarSlavchev Savov |
| DimitarSlavchev Savov | ||
| Chief Executive Officer, Director |
This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
17